InSite ties up with Quest on glaucoma test:
This article was originally published in Clinica
Executive Summary
Quest Diagnostics and ophthalmic products company InSite Vision have set up a one-year agreement under which Quest will provide lab services in the US for InSite's OcuGene genetic test for the early prognosis and diagnosis of glaucoma. The OcuGene kit, introduced recently in the US by the Alameda, California company, consists of a pair of buccal brushes used to swab the inside of the patient's cheek. Quest will test the samples for gene mutation at its Nichols Institute site in San Juan Capistrano, California.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.